Track topics on Twitter Track topics that are important to you
Arrowhead’s $36m financing brings in much needed cash, as well as a group of biotech-specialist investors, which should move it up a league as it embarks on the clinical development of its hepatitis B treatment ARC-520. Pro forma cash of $36m should be sufficient to advance ARC-520, which is now central to the investment case, through to proof-of-concept (PoC) data, which we expect to be a major value inflection point. We have revised our rNPV to reflect the fund-raising and now indicate a value of $121.6m or $3.85 per basic share and $3.11 per diluted share (assuming full conversion of convertible notes plus warrants).
Source: Edison Investment - read full article at http://www.edisoninvestmentresearch.com/NEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...